Evotec SE : Strong earnings growth should come into focus again
>Strong slump in share price unjustified - Despite the reduction in our earnings estimates and the associated reduction in our TP to € 26, we still see an attractive buying opportunity. The substantial share price loss since the resignation of CEO Werner Lanthaler in no way reflects the company's operational potential. We do not see any danger of legal risks for the company from Mr Lanthaler's compliance violations, nor do we see that the operating business is impaire...Evotec is a holding company engaged as a drug discovery solutions company providing drug discovery capabilities to pharmaceutical and biotechnology companies as well as to academic institutions. These drug discovery solutions are provided in form of fee-for service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Co. is primarily involved in the areas of neuroscience, pain, metabolic diseases, oncology and inflammation. Co. provides its drug discovery activities under the banners of EVT Execute, EVT Integrate and EVT Innovate. Co.'s operations are divided into two segments: EVT Execute and EVT Innovate.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.